Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05885360 · ClinicalTrials.gov registry record · Phase 4
Istradefylline Effect Protocol on Parkinson's Disease Tremor
A Phase 4 study of Parkinson Disease and Tremor, sponsored by Georgetown University.
- Completed
- Registry status
- Phase 4
- Development phase
- 27
- Enrollment target
- 1
- Study location
NCT05885360 is a Phase 4 study of Parkinson Disease and Tremor that has completed, run by Georgetown University. The registered enrollment target is 27 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05885360, a Phase 4 study of Parkinson Disease and Tremor, has completed, sponsored by Georgetown University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 27 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an investigator-initiated trial. In this 6-month open label, single arm, exploratory pilot study, the investigator intends to enroll a pilot sample of 25 patients with Parkinson's disease who are being started on the novel FDA approved medication "Istradefylline'' as an add on therapy for management of their motor symptoms (based on the judgment of the movement disorders specialist, if patients are in sub-optimal management of their symptoms on maximum tolerable dose of their dopaminergic medications). The investigator will evaluate their motor symptoms before starting the new medication, including their MDS-UPDRS total and MDS-UPDRS-III scores.
Conditions Studied
Interventions
- DRUG Istradefylline Pill
Study Locations (1)
Virginia
- Georgetown University Hospital - McLean
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2023-01-20 |
| Est. Completion | 2025-02-21 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05885360
The ClinicalTrials.gov registry entry for NCT05885360 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower). The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Parkinson Disease appearing as the primary indexed condition, and to 1 intervention - of which Istradefylline Pill is the first listed.
NCT05885360 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT05885360 about?
NCT05885360 is a clinical study titled "Istradefylline Effect Protocol on Parkinson's Disease Tremor". This is an investigator-initiated trial. In this 6-month open label, single arm, exploratory pilot study, the investigator intends to enroll a pilot sample of 25 patients with Parkinson's disease who are being started on the novel FDA approved medication "Istradefylline'' as an add on therapy for ma...
What is the current status of trial NCT05885360?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 27 participants. The study started on 2023-01-20. Estimated completion is 2025-02-21.
What conditions does trial NCT05885360 study?
This clinical trial studies the following conditions: Parkinson Disease, Tremor.
What interventions are being tested in trial NCT05885360?
The interventions under investigation include: Istradefylline Pill (DRUG).
Who is sponsoring clinical trial NCT05885360?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05885360 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
BOOST-PD A Naturalistic Study on IPX-203 for Parkinson's Disease
RECRUITING · Phase 4
-
Cortical Electrophysiology of Response Inhibition in Parkinson's Disease
RECRUITING · Phase 4
-
A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease
RECRUITING · Phase 4
-
Personalized Real-Time DBS and PD Mechanisms
RECRUITING · Phase 4
-
Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases
RECRUITING · Phase 4
-
Trial of Parkinson's And Zoledronic Acid
ACTIVE NOT RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.